Yeul Hong Kim
Overview
Explore the profile of Yeul Hong Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
211
Citations
4127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blechter B, Hsiung C, Wang X, Zhang H, Seow W, Shi J, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581378
We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the EGFR gene in 998 East Asian never-smoking female LUAD...
2.
Lim A, Kim B, Kim J, Hyun M, Park K, Kim Y, et al.
Front Oncol
. 2024 Jul;
14:1390452.
PMID: 39070139
Background: This phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and determine the maximal tolerated dose (MTD) and...
3.
Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, et al.
medRxiv
. 2024 Jul;
PMID: 38978671
Polygenic risk scores (PRSs) are promising for risk stratification but have mainly been developed in European populations. This study developed single- and multi-ancestry PRSs for lung adenocarcinoma (LUAD) in East...
4.
Lee D, Park S, Kim Y, Lee Y, Shin S, Ahn B, et al.
Oncoimmunology
. 2024 Jun;
13(1):2371563.
PMID: 38919826
Trial Registration: The trial was registered at ClinicalTrials.gov under the identifier NCT03785496.
5.
Koo D, Jung M, Kim Y, Jeung H, Zang D, Bae W, et al.
Cancer Res Treat
. 2024 May;
56(4):1136-1145.
PMID: 38697849
Purpose: Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase...
6.
Choi J, Park K, Kim Y, Sa J, Sung H, Chen Y, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Feb;
33(5):712-720.
PMID: 38393316
Background: Microsatellite instability (MSI) and tumor mutational burden (TMB) are predictive biomarkers for pan-cancer immunotherapy. The interrelationship between MSI-high (MSI-H) and TMB-high (TMB-H) in human cancers and their predictive value...
7.
Kim J, Cha Y, Shin S, Park Y, Kang J, Kim C, et al.
Anticancer Res
. 2023 Dec;
44(1):347-359.
PMID: 38160001
Background/aim: This study investigated the treatment patterns and prognosis of patients with metastatic or unresectable colorectal cancer (mCRC) treated with chemotherapy with targeting agents. Patients And Methods: This longitudinal multicenter...
8.
Shi J, Shiraishi K, Choi J, Matsuo K, Chen T, Dai J, et al.
Nat Commun
. 2023 May;
14(1):3043.
PMID: 37236969
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study...
9.
Catenacci D, Kang Y, Uronis H, Lee K, Ng M, Enzinger P, et al.
Oncology (Williston Park)
. 2023 Apr;
37(4):176-183.
PMID: 37104758
Purpose: To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded by ERBB2)-positive gastric/gastroesophageal adenocarcinoma (GEA) who progressed on or after trastuzumab-containing treatments were...
10.
Ryu M, Lee K, Shen L, Yeh K, Yoo C, Hong Y, et al.
Cancer Med
. 2022 Dec;
12(7):7784-7794.
PMID: 36515003
Background: In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first-line chemotherapy in advanced gastric cancer. Patients...